First, earlier findings were largely driven by the proliferation rate of LCLs as a surrogate ex-vivo biomarker for neuroplasticity, while the current study stratified donor patients on diagnostic (only unipolar depression) and therapeutic (SERT-inhibiting ADs) profiles to obtain an as homogenous cohort as feasible. Here, SLC6A4 is linked to major depressive disorder.